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Genetic variants affecting hematopoiesis can influence commonly measured blood cell traits. To identify factors that affect hematopoiesis, we performed association studies for blood cell traits in the population-based Estonian Biobank using highcoverage whole-genome sequencing (WGS) in 2,284 samples and SNP genotyping in an additional 14,904 samples. Using up to 7,134 samples with available phenotype data, our analyses identified 17 associations across 14 blood cell traits. Integration of WGS-based fine-mapping and complementary epigenomic datasets provided evidence for causal mechanisms at several loci, including at a previously undiscovered basophil countassociated locus near the master hematopoietic transcription factor CEBPA. The fine-mapped variant at this basophil count association near CEBPA overlapped an enhancer active in common myeloid progenitors and influenced its activity. In situ perturbation of this enhancer by CRISPR/Cas9 mutagenesis in hematopoietic stem and progenitor cells demonstrated that it is necessary for and specifically regulates CEBPA expression during basophil differentiation. We additionally identified basophil count-associated variation at another more pleiotropic myeloid enhancer near GATA2, highlighting regulatory mechanisms for ordered expression of master hematopoietic regulators during lineage specification. Our study illustrates how population-based genetic studies can provide key insights into poorly understood cell differentiation processes of considerable physiologic relevance.
genome sequencing | GWAS | basophils | hematopoiesis | CEBPA T he human hematopoietic system is among the best understood paradigms of cell differentiation in physiology (1) . However, despite our sophisticated understanding, many aspects of this process remain poorly understood. In particular, although hematopoiesis is perturbed in a variety of human blood disorders and shows considerable interindividual variation, the underlying basis of the disease etiology and variation remains incompletely understood. Genetic variation in hematopoiesis can be reflected in commonly measured laboratory values, such as hemoglobin levels or blood cell counts. Rare mutations disrupting genes involved in hematopoiesis can result in severe abnormalities in various blood cell counts (2) . Common genetic variants affecting hematopoiesis can also subtly influence blood cell measurements in the general population and can alter the clinical manifestations in rare blood disorders (1, (3) (4) (5) . Genetic studies offer a unique opportunity to gain insight into the hematopoietic system without being biased by our prior knowledge.
The Estonian Biobank is a population-based biobank that has collected DNA samples from 51,535 individuals representing ∼5% of the Estonian population (6) . This cohort is composed of adults representative of the larger Estonian population in terms of age, sex, and geographic distribution. The biobank has particular value because electronic medical records (EMRs) in Estonia are centralized and all participants have consented to allow full access to their medical records, providing an excellent resource to investigate the underlying genetic basis for a variety of traits and diseases. Moreover, many of the samples from the biobank have undergone extensive genomic characterization, including single-nucleotide polymorphism (SNP) genotyping from 14,904 nonoverlapping individuals and PCR-free, high-coverage whole-genome sequencing (WGS) from 2,284 individuals. Here,
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Human blood cell production is coordinated to ensure balanced levels of all lineages. The basis of this regulation remains poorly understood. Identification of genetic differences in human populations associated with blood cell measurements can shed light on such regulatory mechanisms. Here, we used whole-genome sequencing data to perform a genetic association study in a population-based biobank from Estonia. We identified a number of potential causal variants and underlying mechanisms. For example, we identified a regulatory element that is necessary for basophil production, which acts specifically during this process to regulate expression of the transcription factor CEBPA. We demonstrate how genome sequencing, genetic fine-mapping, and functional data can be integrated to gain important insight into blood cell production.
to gain insight into hematopoiesis and regulatory mechanisms underlying this process, we have taken advantage of the valuable resource afforded by the Estonian Biobank to perform genetic association studies of all blood cell measurements available in this large population-based cohort.
Results
Study Overview. To perform the genetic association studies for blood cell traits, we used the WGS of 2,284 individuals and the SNP genotypes of 14,904 individuals from the Estonian Biobank. The WGS data underwent joint variant calling, followed by extensive sample and variant-level quality control (QC) (Dataset S1 and Fig. S1 ). The SNP genotypes were imputed to a custom reference panel constructed from the high-coverage Estonian Biobank WGS data. The custom imputation panel included all single-nucleotide variants present in the WGS with allele count of ≥3 in the WGS, representing a total of 16,536,512 imputed variants.
Using the genotype data described above, we tested for associations with 14 blood cell measurements. This included measurements reflective of red blood cell (RBC) numbers, size, and other related parameters [hemoglobin, hematocrit, RBC count, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC)]; platelet numbers and size [mean platelet volume (MPV)]; as well as white blood cell subtype numbers (absolute numbers of neutrophils, monocytes, lymphocytes, eosinophils, and basophils). As expected, these measurements are often strongly correlated with each other (Fig. S2) . Because all individuals in the Estonian Biobank consented to provide access to their corresponding EMR data, we were able to greatly expand sample sizes in a resource-efficient manner. For a subset of randomly selected individuals, blood cell measurements were directly assayed in a clinical laboratory (hereafter referred to as "lab-based") (Datasets S2 and S3 and Figs. S3 and S4). For most individuals, we mined the EMR to extract blood cell measurements when available. As each individual might have multiple measurements in the EMR, we used the median value for each individual after correcting for age, sex, location, and type of measurement (laboratory or EMR-based). In general, the laboratory-based and EMR-based values were strongly correlated; however, the measurements of certain traits, especially of white blood cell subtypes, were variable and had lower correlations (Fig. S4) . In total, for each trait, we had between 4,221 and 7,134 samples with genotype and phenotype data (Dataset S2). We performed single-variant association analyses on all variants with a minor allele count of ≥3. We also performed gene-based burden testing of rare variants [minor allele frequency (MAF) < 5%] using SKAT-O (7).
Blood Cell Trait Associations in the Estonian Biobank. The singlevariant analysis revealed a total of 17 genome-wide significant associations (P < 5 × 10 −8 ) across the various blood cell measurements (Table 1) . Sixteen of these associations had been identified previously and highlight important biological mechanisms, such as associations at the HBS1L-MYB locus that contains at least three independent variants showing pleiotropy with multiple blood cell measurements (Dataset S4) (3, 8, 9) . This locus is of considerable interest because the blood trait-associated variants within this region are associated with the severity of the major hemoglobin disorders, sickle cell disease and β-thalassemia (9-11). Other loci that we identified here contain well-known hematopoietic regulators such as JAK2 (associated with platelet counts) (12, 13) and F2RL2 (associated with MPV) (14) . In contrast to the genomewide association studies (GWASs) involving common variants, the gene-based burden testing (which seeks to aggregate rare variants in each gene) did not identify any significant associations (at P < 8.33 × 10
−7
). Although studies (such as ours) that use whole-genome sequencing rather than genotyping a fixed set of genetic markers have obvious advantages in terms of detecting rare variants (15), we note that our sample is likely underpowered for comprehensive rare-variant analysis, which is expected to require sample sizes in the range of tens of thousands of individuals (16) .
The strongest effect identified was a previously undiscovered association with basophil counts near the gene encoding CCAAT/ enhancer-binding protein alpha (CEBPA) (rs78744187; P = 6.19 × 10 −38 ) ( Fig. 1 and Fig. S5 ). Each minor allele of this SNP is associated with a 5.9 (per microliter) decrease in basophil counts and the SNP remarkably explains 4.4% of phenotypic variance (Table 1) . To ensure that this association is not driven by extreme or spurious values from EMR-based measurements, we validated the association using only laboratory-based measurements with outliers removed (P = 3.31 × 10
−15
). Furthermore, to ensure that this association is not population-specific, we examined this SNP in 7,488 individuals from three US-based European ancestry cohorts and observed a significant association with basophil counts (P = 5.99 × 10 −7
; Fig. S6A ). Despite the remarkably large effect size of this SNP, previous GWAS for basophil counts have not detected this association (17) (18) (19) . This is likely because previous studies were imputed to a sparser reference panel (HapMap). Because none of the variants present in HapMap tag rs78744187 strongly, these studies would have failed to detect this association (Fig. S6B ). This observation demonstrates how denser reference panels or comprehensive genome sequencing data can enable the discovery of additional common variants associated with human traits and diseases.
To assess the comprehensiveness of our analysis ( Fig. S7 ), we compared all of the variants identified by genome sequencing at each locus with the 1000 Genomes (1000G) reference panel (20) . Although our study identified variants in significant linkage disequilibrium (LD) with the lead SNP (r 2 > 0.5) that were absent from the 1000G phase 1 reference panel, all of these variants were present in phase 3 (21) . Importantly, no variants identified in significant LD with the lead SNP (r 2 > 0.5) in 1000G were missing from our analysis. In addition, there were no copy number variants (CNVs) within 1 Mb that were in LD (r 2 > 0.5) with any of the observed associations (Dataset S5). Given these results, we were confident that all potential causal variants had been captured by our analyses and our custom WGSbased reference panel was genuinely reflective of the study population, which are both important prerequisites for fine-mapping.
Fine-Mapping Genetic Associations. Although most of the associations have been previously detected, none have yet been pinpointed to specific variants. To attempt to identify the likely causal variant at each locus, we performed statistical finemapping analyses, which use LD patterns and association statistics to generate the probability that any particular variant at a locus of interest is causal. We applied three methods for finemapping [approximate Bayes factor (ABF), CaviarBF, and PICS] (22-24) and, for each, generated a credible set (CS) of variants, which has a 97.5% probability of containing the casual variant. The CSs generated with ABF and CaviarBF exhibited near-perfect concordance, whereas the CSs generated with PICS, although in strong agreement at most loci, included substantially more variants for three of the loci (Fig. S8) . As these additional variants nominated solely by PICS were generally of low r 2 to the sentinel association, the intersection of ABF and CaviarBF was chosen as the final CS. Remarkably, at 4 of the 13 independent loci (MPV/platelet counts at 3p14, platelet counts at 9p24, MPV at 12q24, and basophil counts at 19q13), our fine-mapping results resolved the association signal to a single putative causal variant. At two other loci, the CSs had three and five variants ( Overlap with Epigenomic Data Suggests Causal Mechanisms. An estimated 80-90% of causal GWAS signals are noncoding variants that presumably act by altering expression of nearby genes (25, 26) . To define potential causal mechanisms of the variants, we overlapped CS variants with nucleosome-depleted regions (NDRs) identified by assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq) from 13 primary human cell types (27) , comprising the majority of the hematopoietic hierarchy. For 35 CS variants (out of 186 variants from 17 loci; 18.8%), we identified an overlap with hematopoietic NDRs, a significant enrichment compared with non-CS variants in moderate to high LD (r 2 > 0.5) (OR = 2.41, P = 0.0009). Additionally, a permutation test involving local shifting of the NDRs around the CS variants revealed a significant enrichment (1.87-fold change in overlap, P = 0.00042) (28) . Furthermore, at 11 of 13 independent loci (85%), at least one CS variant overlapped a NDR ( Fig. 2A) . Of note, only the remaining two loci contained a genic variant in their CSs (Table 1) . At TMPRSS6 associated with MCH, there is a missense variant (rs855791, p. V736A) in strong LD with the lead SNP (r 2 = 0.82). Rare damaging mutations in TMPRSS6 cause iron-refractory irondeficient anemia, and this particular variant has been previously reported to influence iron homeostasis (29, 30) . At the 9q31 locus associated with monocyte counts, there are two variants (rs59364245 and rs60698178) located in an uncharacterized long noncoding RNA.
For example, at the well-known HBS1L-MYB locus (8), 11 variants associated with multiple red blood cell and platelet traits overlap with a NDR in at least one stage of hematopoiesis. Seven of these variants overlap with predominately erythroid-specific NDRs (Fig. 2 A and B) . Although our results agreed with previous studies that variants in the −84-and −71-kb elements are putative functional variants (31), we also identified a previously uncharacterized −83-kb erythroid element harboring three CS variants that may also have regulatory function (Fig. S9) . Notably, for all four of the association signals that we finemapped to a single variant, the identified variant overlaps with a hematopoietic NDR ( Table 1) . As an example, we were able to fine-map the association with MPV and platelet counts on 3p14 to rs1354034. This variant overlaps with a common-myeloid progenitor (CMP)-and megakaryocyte-erythroid progenitor (MEP)-specific regulatory element that has previously been shown to affect the transcription of nearby ARHGEF3, a factor implicated in hematopoiesis ( Fig. 2A and Fig. S10 ) (32) . Interestingly, the rs1354034 variant is associated (in trans) with the expression of von Willebrand factor (VWF) and other key platelet/megakaryocyte genes found at other loci, suggesting a role for this variant in the development of this lineage (33, 34) . In all of these examples, our comprehensive ascertainment of genetic variation gave us confidence that the causal variant is included among the variants we analyzed.
To further explore the putative regulatory modalities of these CS variants, we investigated the overlap of CSs with transcription factor (TF) occupancy, functional regulatory models, and predicted motif disruptions. Based upon functional models trained on TF occupancy, open chromatin, and histone modifications, CS variants were enriched for functional regulatory variants (Fig.  S11) (35) . Because TF occupancy profiles were not available for the entire hematopoietic hierarchy, we inferred putative TF overlap by investigating the overlap of CS variants with 4,559 publicly available ChIP-seq datasets from human blood-based tissues and cell lines. These analyses revealed putative mechanisms for a number of variants and provide testable hypotheses, which are particularly tractable for the four CSs containing only a single variant (Datasets S7 and S8). For example, rs1354034, which we described above as being within a NDR near ARH-GEF3, disrupts a conserved GATA motif. In addition, Gata1 occupies the orthologous mouse region containing this variant in megakaryocytes, but not erythroid cells, suggesting a putative mechanism by which this variant may act (Fig. S12) .
Basophil Associations Illuminate Mechanisms for Hematopoietic
Lineage Specification. We next turned to the association with basophil counts at 19q13 near CEBPA. As we noted above, this locus could be resolved to a single putative causal variant, rs78744187, which resides 39 kb downstream from CEBPA, near a separate +42-kb enhancer that has been shown to influence CEBPA expression along various myeloid lineages (36) (37) (38) . rs78744187 appeared to be solely associated with basophil counts and showed no evidence of pleiotropic effects on other blood cell traits, including among other myeloid lineages (Dataset S4). Conditioning the association on the rs78744187 genotypes attenuated all signals at the locus, suggesting the existence of only one independent signal at the locus (Fig. S13) . Interestingly, rs78744187 resides within a distinct NDR present only in CMPs, but not in granulocyte-monocyte progenitors (GMPs), consistent with emerging data for a GMP-independent origin for basophils, mast cells, eosinophils, and their progenitors (Fig. 3A) (39-42) . Moreover, this NDR is weakly to moderately present in myeloid cell lines from mice and humans (HL60, K562, HPC7, and CMK) and is occupied by numerous myeloid transcription factors, including master regulators of myeloid differentiation: GATA2 and RUNX1 (Dataset S7 and Fig. S14 ). In a luciferase reporter assay, the +39-kb region demonstrated enhancer activity (∼40-fold increase in activity relative to the minimal promoter) in the K562 myeloid cell line. Additionally, the basophil count-decreasing rs78744187-T allele was associated with a 28.6% reduction in enhancer activity (Fig. 4A) . Despite extensive analyses of TF occupancy and alterations to predicted TF motif, we were unable to elucidate an exact mechanism for how this variant modulates enhancer activity, as is frequently noted to be the case for putative causal variants that alter gene expression (4, 24) . Taken together, these data show that the +39-kb region contains a myeloid enhancer element that is active in CMPs and that shows variation in activity modulated by the rs78744187 variant.
To identify the gene(s) whose expression is modulated by rs78744187 to influence basophil production, we performed in situ perturbation of the +39-kb enhancer using CRISPR/Cas9-mediated mutagenesis in CD34 + human hematopoietic stem and progenitor cells (HSPCs) (43) . We targeted the +39-kb enhancer using two guides that flank the rs78744187 variant (Fig. 4B) . Deep sequencing of the target regions showed that both guide RNAs caused insertions or deletions at a high efficiency (∼88%) (Fig. 4C) . We observed a 60% reduction in CEBPA expression in the nonclonal population of enhancer-disrupted hematopoietic cells compared with controls (Fig. 4D) . As enhancer-promoter looping interactions primarily occur within topologically associated domains (TADs), we investigated all other expressed genes in the TAD harboring this variant but did not observe any significant changes in their expression (Fig. 4D and Fig. S15 ) (36) . Interestingly, perturbation of this element in the granulocyte/monocyte cell lines HL60 and U937 did not result in any major alteration of CEBPA expression (Fig. S16) , demonstrating the specificity of this regulatory element during basophil differentiation.
The TF CEBPA has been previously implicated in basophil specification, in particular during the bifurcation from the developmentally related mast cell lineage (44) (45) (46) . However, CEBPA is also implicated more broadly in hematopoiesis as a master TF (36, 47, 48) , suggesting that its expression is temporally regulated to specify basophils and other terminal lineages (49) . To test whether the +39-kb enhancer provides the temporal regulation of CEBPA expression for proper basophil differentiation, we performed directed differentiation of the CRISPR/Cas9 enhancer-mutagenized HSPCs in the presence of IL-3 (50-52).
IL-3-mediated differentiation of human CD34
+ cells predominately generates basophils but can generate mast cells to a lesser degree (50, 53, 54) . Following 2 wk in culture, ∼51% of cells expressed basophil surface marker phenotypes (CD203c (Fig. 5B) . Morphologically, 25% of the cells in these cultures resembled mature basophils, suggesting that our cultures may also accommodate less mature precursors of these lineages as well, which is in agreement with the observation that the CD203c antibody can detect mature human basophils, mast cells, and their precursors (53) . The enhancer-mutagenized cells showed a significant reduction in basophil production based upon cell surface markers and morphology, as well as a proportionate increase in immature mast cells compared with controls (Fig. 5 A-D and Fig. S17 ). In addition, the basophils produced in the enhancermutagenized cells frequently showed impaired maturation with a paucity of basophilic granules and a high frequency of empty or eosinophilic granules instead (Fig. 5 C and D) . These results demonstrate that an intact +39-kb enhancer is required for proper expression of CEBPA during basophil differentiation and maturation. Alternatively, the +39-kb CEBPA enhancer may regulate cytoplasmic granule development in basophils, independent of its effects on differentiation. Our results also extend earlier studies in mice that suggested a key role for Cebpa in modulating the basophil/mast cell lineage fate choice (55, 56) . Our GWAS also identified an association with basophil counts at 3q21, which includes another master TF: GATA-binding protein 2 (GATA2) (rs2465283, P = 9.99 × 10 −12 ) (Fig. 1A and Table  1) . A previous GWAS performed in a Japanese population also identified an association at this locus with basophil counts (rs4328821; P = 5.3 × 10 −40 ) (18). We noted that the basophildecreasing allele of rs4328821 is associated with decreased GATA2 expression in whole blood (P = 5.3 × 10 −13 ) (57). By leveraging differences in the LD patterns between Estonians and East Asians and examining only variants in strong LD (r 2 > 0.8) with the lead SNP in both populations, we were able to reduce our CS from 11 to 6 variants. Of these six CS variants, only one variant (rs6782812) overlapped a strong hematopoietic NDR. Surprisingly, similar to the CEBPA variant (rs78744187), this NDR is also CMP specific (Fig. 3B) and is occupied by the RUNX1 and GATA2 TFs (Fig. S18) . In luciferase-based assays in K562 cells, the NDR demonstrates ∼4.5-fold enhancer activity and the fine-mapped GATA2 variant (rs6782812) reduced enhancer activity by 69% (Fig. S18A) . Because there are common master TFs at the two basophil-associated loci (GATA2 and CEBPA), we examined whether these two loci might show an epistatic interaction. We found no evidence of epistasis between rs2465283 (GATA2) and rs7874418 (CEBPA) (P = 0.070). The GATA2-associated variant was also associated with eosinophil counts (P = 3.07 × 10 −3 ; Dataset S4), as has been seen previously in other studies (17) (18) (19) 58 ). An independent association near GATA2 for monocyte counts has been reported by other studies (monocyte sentinel SNP rs9880192; r 2 = 0.054 to rs2465283 in Europeans) (17, 19) . These associations near GATA2 are consistent with the well-known role of GATA2 in driving myeloid differentiation (59, 60) . Together, these results suggest that the fine-mapped GATA2 variant (rs6782812) influences lineage specification at an earlier myeloid progenitor that is capable of producing basophils, eosinophils, and potentially other lineages, whereas the CEBPA variant (rs78744187) appears to be present in an enhancer that is specifically necessary for production of basophils from a downstream bipotential basophil/mast cell progenitor (BMCP) or other myeloid progenitor (Fig. 5E ).
Examination of Disease Associations. Basophils have been implicated in inflammation and host defense, but the causal role that basophils play in human disease is poorly understood (44, (61) (62) (63) . To identify potential disease roles for basophils, we performed a phenome-wide association study (pheWAS) for rs78744187 and rs2465283 (64) . To accomplish this, for each available International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10) medical billing code, we treated all individuals with the code as cases and treated anyone without the code as a control. We tested for the existence of associations between either variant and all 534 diseases that had greater than 100 cases. No disease associations reaching the P value threshold of 9.2 × 10 −5 (following Bonferroni correction) were identified for either SNP. However, rs78744187 was nominally associated with joint derangements and enteropathic arthropathy (P values of 0.00023 and 0.00059, respectively), which may have autoinflammatory etiologies (Dataset S9). Previous studies have identified multiple associations with inflammatory bowel disease (IBD) near CEBPA (65-67). However, the basophil association at rs78744187 appears to be independent from the IBD associations (Dataset S10). We do note that, although disease associations with basophil counts are likely to exist, similar to those seen with the related eosinophil lineage, we are likely to be underpowered in our current study to robustly detect such an effect, particularly given the variable fidelity of medical coding (Fig. S19) (68) .
Discussion
In this study, we integrated WGS-based GWASs, fine-mapping, epigenomic datasets, and functional assays to provide additional insight into our evolving understanding of lineage specification during human hematopoiesis (69, 70) . Integration of comprehensive genetic and extensive epigenomic data at these loci provided key insight into human hematopoietic regulatory mechanisms. For example, we were able to identify a variant that likely affects GATA1 TF binding to influence expression of ARHGEF3 during Results are reported as mean and SD across three independent experiments (n.s., not significant; ***P < 0.0001).
megakaryopoiesis. At the extensively studied HBS1L-MYB locus, by overlapping fine-mapping data with extensive ATAC-seq data, we provided evidence for additional putative causal variants. By integrating these complementary datasets, we were able to generate experimentally tractable hypotheses for further functional investigation. At one of these loci, we fine-mapped a previously undiscovered association with basophil counts near the master TF CEBPA to a CMP-restricted enhancer element. Functional assays revealed that the causal variant altered enhancer activity and resulted in decreased CEBPA expression, which therefore helps drive the lineage choice between basophils and mast cells. Whether this lineage choice happens at the BMCP or a different myeloid progenitor stage is currently not resolved, and because our GWAS study did not measure mast cells in nonhematopoietic tissues, our findings cannot directly address this issue (71, 72) . In the region of another master TF, GATA2, our study identified a basophil and eosinophil count-associated variant within a similar CMP-restricted enhancer associated with GATA2 expression. Thus, our study provides evidence that common genetic variation regulates basophil production by tuning the ordered expression of master TFs through the alteration of stage-specific enhancer elements (49) . Furthermore, as both basophil-associated variants fall within enhancer elements that are active specifically in CMPs (but not GMPs or MEPs), our study provides strong support for revised models of hematopoiesis, where eosinophils, basophils, mast cells, and their progenitors bifurcate at the earlier CMP stage, rather than the more traditional models where these lineages arise from GMPs along with granulocyte and monocyte progenitors (Fig. 5E) (41, 42) . Our findings provide key insights into the molecular regulation of basophil production, an important and nonredundant cell type in inflammation and host defense that has been challenging to study in humans due to its rarity (44, (61) (62) (63) . The identification of these variants will also allow for further studies of the mechanisms by which genetic variants influencing basophil counts may impact on human diseases.
Our study also demonstrated the benefits of using high-coverage WGS in a population-based biobank. Comprehensive ascertainment of genetic variation allowed us to identify the association near CEBPA, which would have been missed had we imputed to sparser reference panels, such as HapMap. Furthermore, the high-coverage WGS allowed us to comprehensively capture variation that might be missed by lower coverage sequencing approaches (such as longer indels and variants in low-complexity regions), giving us confidence that the true causal variant has been identified at each locus, an important prerequisite for fine-mapping. Moreover, by performing our study in a population-based biobank, we were also able to link genetic data with EMRs to greatly increase sample sizes in a resourceefficient manner, providing support for similar programs such as the Precision Medicine Initiative (73) . Together, our study demonstrates how key genetic and biological insights can be gained from comprehensive genetic studies in population-based biobanks.
Materials and Methods
Blood Cell Measurements. We performed a complete blood count (CBC) in a clinical laboratory ("lab-based") for 2,000 participants. One thousand individuals were chosen for profiling based on their agreement to be part of a recall study (mean follow-up time, 4.5 y) for collecting new biological samples and data on health and lifestyle. The remaining 1,000 samples represent For each individual, we used the EMR-based measurements only if laboratory-based values were not available. We removed spurious values and extreme outliers (Dataset S3). We then performed regression using a linear mixed model adjusting for sex as a fixed effect, and setting (EMR-based vs. laboratory-based, as well as the specific hospital/clinic) and age at measurement as random effects. We took the median residual for each individual and performed inverse normal transformation of the median residuals. These median residuals were used for downstream association analyses.
Generation of genome sequencing data, variant calling, imputation, and association testing are all described in SI Materials and Methods. Approval for this study was obtained from the institutional review boards of the University of Tartu, Massachusetts Institute of Technology, and Boston Children's Hospital. Informed consent was provided according to the Declaration of Helsinki.
Luciferase Reporter Assays. The genomic regions containing major and minor allele of the variants rs78744187 (∼400 bp) and rs6782812 (∼364 bp) were synthesized as gblocks (IDT Technologies; Dataset S11) and cloned into the firefly luciferase reporter constructs (pGL4.24) using BglII and XhoI sites. The firefly constructs (500 ng) were cotransfected with pRL-SV40 Renilla luciferase constructs (50 ng) into 100,000 K562 cells using Lipofectamine LTX (Invitrogen) according to the manufacturer's protocols. Cells were harvested after 48 h and the luciferase activity measured by Dual-Glo Luciferase Assay system (Promega).
Genome Editing in Human CD34
+ HSPCs Using Lentiviral CRISPR/Cas9 Mutagenesis.
Two guide RNAs targeting the variant rs78744187 and a control guide RNA targeting GFP (Fig. 4B) were cloned into LentiCRISPRv2 constructs (74) . The constructs along with packaging helper constructs were transfected into HEK-293T cells for lentiviral production. The viral supernatant was then concentrated 60 times by ultracentrifugation. Human CD34 + HSPCs (adult) were purchased from Seattle Fred Hutchinson Center and cultured in Iscove's modified Dulbecco's medium with 10% (vol/vol) FBS in the presence of human IL-3 (10 ng/mL). On day 2 in culture, ∼500,000 cells were spinfected with the concentrated lentiviral supernatant and polybrene (8 μg/mL) on retronectin-coated plates (Takara). On days 5 and 6 in culture, the cells were selected with puromycin (1 μg/mL). CEBPA expression was measured at day 7 in culture. The cells were subsequently cultured until day 14 for differentiation into basophils and mast cells.
Genome Editing in HL60s and U937 Cell Lines Using Lentiviral CRISPR/Cas9. HL60 and U937 cells were cultured in RPMI with 10% (vol/vol) FBS. One to 2 million cells were spinfected with lentiviral supernatant with polybrene (8 μg/mL). On days 3, 4, and 5 postspinfection, cells were selected with puromycin (1 μg/ mL). CEBPA expression was measured at day 12 postspinfection. For the Surveyor assay, genomic DNA was extracted at day 12 and a 600-bp region containing the CRISPR cut sites was PCR amplified (Dataset S11). The Surveyor assay was performed according to kit recommendations (IDT Technologies).
Flow Cytometry. Cells were incubated with Human BD Fc Block (BD Biosciences) for 10 min at room temperature to prevent nonspecific binding to Fc receptors. Subsequently, the cells were stained with CD117-PE (clone 104D2; Biolegend) and CD203c-APC (clone NP4D6; Biolegend) antibodies and analyzed by BD Accuri Flow Cytometer. FACS plots were generated by FlowJo (Tree Star).
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